A look at infectious agents as a possible causative factor in cardiovascular disease: Part II

Laboratory Medicine

Volumn 34, Issue 4, 2003, Pages 288-292

  Vojdani, Aristo ^a  

^a Immunosciences Laboratories Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; AZITHROMYCIN; BACTERIAL DNA; CYTOTOXIN; IMMUNOGLOBULIN G ANTIBODY; MYOSIN;

ATHEROSCLEROSIS; AUTOIMMUNITY; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; BACTERIUM IDENTIFICATION; CARDIOVASCULAR DISEASE; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; DISEASE ASSOCIATION; DISEASE MARKER; HELICOBACTER PYLORI; HUMAN; NONHUMAN; PATHOGENESIS; PATHOGENICITY; POLYMERASE CHAIN REACTION; REVIEW; SERODIAGNOSIS; SEROPREVALENCE; SEXUALLY TRANSMITTED DISEASE;

BACTERIA (MICROORGANISMS); CHLAMYDOPHILA; CHLAMYDOPHILA PNEUMONIAE; HELICOBACTER; HELICOBACTER PYLORI;

EID: 0037385957     PISSN: 00075027     EISSN: None     Source Type: Journal    
DOI: 10.1309/H69T-K3BF-4W2Q-2CUF     Document Type: Review

References (56)

1. Grayston JT, Kuo C, Wang S, et al. A new Chlamydia psittaci strain, TWAR, isolated in acute respiratory tract infections. N Engl J Med. 1986;315:161-169.
2. Saikku P, Leinone M, Mattila K, et al. Serologic evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet. 1988;2:983-986.
3. Bowman J, Soderberg S, Forsberg J, et al. High prevalence of Chlamydia pneumoniae DNA in peripheral blood mononuclear cells in patients with cardiovascular disease and in middle-aged blood donors. J Infect Dis. 1991;178:271-277.
4. Byrne GI, Kalayoglu MV. Chlamydia pneumoniae and atherosclerosis: links to the disease process. Am Heart J. 1991;138(5 Pt 2):S481-490.
5. Davidson M, Kuo CC, Middaugh JP, et al. Confirmed previous infection with Chlamydia pneumoniae (TWAR) and its presence in early coronary atherosclerosis. Circulation 98:621-623, 1991.
6. Fong IW, Chiu B, Viira E, et al. De novo induction of atherosclerosis by Chlamydia pneumoniae in a rabbit model. Infect Immun. 1991;67:6041-6055.
7. Gupta S, Kaski JC. Chlamydia causes coronary heart disease: an inflammatory idea? Acute Coronary Syndromes. 1991;1:41-48.
8. Juvonen J, Laurila A, Juvonen T, et al. Detection of Chlamydia pneumoniae in human nonrheumatic stenotic aortic valves. J Am Coll Cardiol. 1991;21:1051-1059.
9. Maas M, Bartelin C, Engel PM, et al. Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease. J Am Coll Cardiol. 1991;31:821-832.
10. Moazed TC, Kuo CG, Grayson JT, et al. Murine models of Chlamydia pneumoniae infection and atherosclerosis. J Infect Dis. 1991;171:881-890.
11. Ong G, Thomas BJ, Mansfield AO, et al. Detection and widespread distribution of Chlamydia pneumoniae in the vascular system and its possible implications. J Clin Pathol. 1991;41:101-106.
12. Shor A, Kuo CC, Patton DC. Detection of Chlomydia pneumoniae in coronary artery fatty streaks and atheromatous plaques. South African Med J 1991;82:151-161.
13. Grayston JT, Mordhorst CH, Wang SP. Childhood myocarditis associated with Chlamydia trachomatis infection. JAMA. 1981;246:2823-2827.
14. Saikku P, Leinonen M, Tenkanen L, et al. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki heart study. Ann Intern Med. 1992;116:273-278.
15. Thom DM, Grayston JT, Siscovitch DS, et al. Association of prior infection with Chlamydia pneumoniae and angiographically demonstrated coronary artery disease. JAMA. 1992;268:68-72.
16. Gupta S, Camm AJ. Chronic infection. Chlamydia and coronary heart disease. Kluwer Academic Publishers. ISBN 1-7921-5791-3. June 1999.
17. Grayston JT. Chlamydia in atherosclerosis. Circulation 1993;87:1408-1409.
18. Kuo CC, Shor A, Campbell LA, et al. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis 1993;167:841-849.
19. Cook PJ, Honeybourne D, Lip GY, et al. Chlamydia pneumoniae and acute arterial thrombotic disease. Circulation. 1995;92:3148-3149.
20. Summersgill JT, Gaydos CA, Schmidt EA, et al. Replication of Chlamydia pneumoniae in human endothelial cells of various origin. In Orfila J, Byrne GI, Chemesky M, et al, eds. Chlamydia infection Bologna, Italy: Societa Editrice Esculapio, 1994;506-509.
21. Moazed TC, Kuo C, Patton DL, et al. Experiment: Rabbit models of Chlamydia pneumoniae infection. Am J Pathol. 1996;148:667-676.
22. Muhlestein JB, Hammond EH, Carlquist JF, et al. Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease. J Am Coll Cardiol. 1996;27:1555-1561.
23. Wimmer MLJ, Sandmann-Strupp R, Saikku P, et al. Association of chlamydial infection with cerebrovascular disease. Stroke. 1996;27:2207-2210.
24. Ramirez JA. Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis: the Chlamydia pneumoniae/Atherosclerosis Study Group. Ann Intern Med. 1996;125:979-982.
25. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet. 1997;350:430-436.
26. Fong IW, Chiu B, Viira E, et al. Rabbit model for Chlamydia pneumoniae infection. J Clinic Microbiol. 1997;35:48-52.
27. Gupta S, Camm AJ. Chlamydia pneumoniae and coronary heart disease: Coincidence, association or causation? BMJ. 1997;314:1778-1779.
28. Jackson LA, Campbell LA, Schmidt RA, et al. Specificity of detection of Chlamydia pneumoniae in cardiovascular tissues: evaluation of innocent bystander hypothesis. Am J Pathol. 1997;150:1785-1790.
29. Hu H, Pierce GN, Zhong G. The atherogenic effects of Chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae. J Clin Investigation. 1999;103:741-753.
30. Blessing E, Lin TM, Campbell LA, et al. Chlamydia pneumoniae induces inflammatory changes in the heart and aorta of mormocholesterolaemic C57BL/6J mice. Inf Immun. 2001;68:4761-4768.
31. Gdoura G, Pereyre S, Frikha I, et al. Culture-negative endocarditis due to Chlamydia pneumoniae. J Clinic Microbiol. 2002;40:718-720.
32. Cook PJ, Honeybourne D, Lip GY, et al. Chlamydia pneumoniae antibody titers are significantly associated with acute stroke and transient cerebral ischaemia: The West Birmingham Stroke Project. Stroke. 1991;29:401-410.
33. Dahlen GH, Bowman J, Birgander LS, et al. Lipoprotein(a), IgG, IgA and IgM antibodies to Chlamydia pneumoniae and HLA class II genotype in early coronary artery disease. Atherosclerosis. 1991;111:161-174.
34. Lindholt JS, Juul S, Vanmen S, et al. Immunoglobin A antibodies to Chlamydia pneumoniae are associated with expansion of abdominal aortic aneurysm. British Journal of Surgery. 1991;86:631-638.
35. Strachan DP, Carrington D, Mendall MA, et al. Relation of Chlamydia pneumoniae serology to mortality and incidence of ischaemic heart disease over 13 years in the Caerphilly prospective heart disease study. BMJ. 1991;311:1031-1039.
36. Linnanmaki E, Leinonen M, Mattila K, et al. Chlamydia pneumoniae-specific circulating immune complexes in patients with chronic coronary heart disease. Circulation. 1993;87:1130-1134.
37. Gupta S, Leatham EW, Carrington D, et al. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation. 1993;87:1130-1134.
38. Vojdani A, Magaziner A, Rogers JT. Detection of Chlamydia pneumoniae infection in patients with atherosclerosis by PCR and enzyme immunoassay, abstract presented at Microbial Linked Diseases: Shifting the Pathogenic Paradigm, June 1998, San Diego, CA.
39. Hoffmeister A, Rothenbacher D, Wanner P, et al. Seropositivity to Chlamydia lipopolysaccharide and Chlamydia pneumoniae. Systemic Inflammation and Stable Coronary Artery Disease. JACC 35(1):111-118, 2000.
40. Shimada K, Mokuno H, Watanabe Y, et al. High prevalence of seropositivity for antibodies to Chlamydia-specific lipopolysaccharide in patients with acute coronary syndromes. J Cardiovasc Risk. 2001;1:210-213.
41. Anderson JL, Muhlestein JB, Carlquist J, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection. The azithromycin in coronary artery disease: Elimination of myocardial infection with Chlamydia (academic study). Circulation. 1991;99:1541-1547.
42. Muhlestein JB, Anderson JL, Hammond EH, et al. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation. 1991;97:631-636.
43. Gurfinkel E, Bozovich G, Daroca A, et al. Randomized trial of Roxithromycin in non-Q-wave coronary syndromes. Lancet. 1991;351:401-407.
44. Mendall MA, Goggin PM, Molineaux N, et al. Relation of Helicobacter pylori infection and coronary artery disease. Br Heart J. 1991;71:431-439.
45. Murray LJ, Bamford KB, O'Reilly DP, et al. Helicobacter pylori infection: Relation with cardiovascular risk factors, ischaemic heart disease, and social class. Br Heart J. 1991;71:491-450.
46. Patel P, Mendall MA, Carrington D, et al. Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. BMJ. 1995;311:711-714.
47. Whincup PH, Mendall MA, Perry IJ, et al. Prospective relations between Helicobacter pylori, coronary heart disease, and stroke in middle-aged men. Heart. 1991;71:561-572.
48. Mendall MA, Giggin PM, Molineaux N, et al. Relation of Helicobacter pylori infection and coronary heart disease. Br Heart J. 1994;71:437-439.
49. Morgando A, Sanseverino P, Perotto C, et al. Helicobacter pylori seropositivity in myocardial infarction. Lancet. 1995;345:1380-1384.
50. Folsom AR, Nieto FJ, Sorlie P, et al. For the Atherosclerosis Risk in Communities (ARIC) study investigators. Helicobacter pylori seropositivity and coronary heart disease incidence. Circulation. 1998;98:845-850.
51. Pasceri V, Cammarota G, Patti G, et al. Association of virulent Helicobacter pylori strains with ischaemic heart disease. Circulation. 1998;97:1675-1679.
52. Ridker PM, Hennekens CH, Buring JE, et al. Baseline IgG antibody titers to Chlamydia pneumoniae, Helicobacter pylori, herpes simplex virus, cytomegalovirus and the risk for cardiovascular disease in women. Ann Intern Med. 1999;131:573-577.
53. Ekesbo R, Nilsson PM, Lindholm LH, et al. Combined seropositivity for H. pylori and C. pneumoniae is associated with age obesity and social factors. Cardiovasc Risk. 2001;1:191-195.
54. Patel HK, Willhite DC, Patel RM, et al. Plasma membrane cholesterol modulates cellular vacuolation induced by H. pylori vacuolating cytotoxin. Infect Immun. 2002;79:4112-4123.
55. Van de Rijn I, Bleiweis AS, Zabriskie JB. Antigens in Streptococcus mutans cross-reactive with human heart muscle. J Dent Res. 1976;55C:59-66.
56. Bachmaier K, Neu N, de la Maza LM, et al. Chlamydia infections and heart disease linked through antigenic mimicry. Science 1999;283:1335-1339.